[Objective] To investigate professor SHAN Zhaowei's experience of diagnosing and treating bile reflux gastritis(BRG). [Method] The experience of Professor SHAN Zhaowei on recognition of etiology and pathogenesis, treatment principle, characteristics of prescription selection and administration of BRG is summarized and studied. Besides his academic ideas and clinical medication experience are shown with typical cases. [Result] In his view, emotional disorder is the most common etiology, and liver-stomach disharmony is the basic pathogenesis. He puts forward that we should pay attention to dispersing the stagnated liver Qi, regulating the stomach to lower the adverse flow of Qi when we treat it, and emphasizes the combination of disease differentiation and syndrome differentiation. Meanwhile, herbs of protecting gastric mucosa are compatibly used to improve the curative effect. And the case in this article has obtained good treatment results. [Conclusion] Pro. SHAN Zhaowei thinks that emotional regulation to patency for patients is very important. The dispersing the stagnated liver Qi, regulating the stomach and protecting gastric mucosa treatment proposed by SHAN Zhaowei is smart, simple and effective, which embodies the characteristic of his healing and MengHe Medicine.

Objective To evaluate the effectiveness and safety of percutaneous hepatic cryoablation combined with percutaneous ethanol injection(PEI) for patients with hepatocellular carcinoma (HCC) unsuitable for surgical resection. Methods One hundred and five masses in 65 HCC patients underwent percutaneous hepatic cryoablation. The cryoablation was performed using Argon gas as a cryogen in the Cryocare System. Two freeze thaw cycles were performed, each reaching a temperature of -180 ℃ at the tip of the probe. PEI was given 1 or 2 weeks after cryoablation and then once a week for 4 6 weeks in 36 patients with tumor mass larger than 6 cm in diameter. Absolute alcohol(100%) was slowly injected into periphery zone of cancerous tissues in liver. Results During average 16 months follow up duration (ranging 5 to 21 months), 32 patients(49.2%) were alive without tumors, and 22 patients (33.8%) were alive with tumor recurrence: two had bone metastases, three lung metastases and the remaining 17 tumor recurrences in the liver, of whom only 3 developed at a cryoalbation site. Among 41 patients who had been followed up more than one year, there were 32(78%) patients who were alive with or without tumor recurrence. Eight patients (12.3%) died of tumor recurrence. Three patients(4.6%) died of noncancer related causes. Among 43 patients who had undergone CT scan, 38 ( 88.4% ) had a shrinkage of tumor mass. Among 22 patients who had received biopsies of cryoablated tumor mass, all but one biopsy showed necrotic or scar tissues. Serum AFP in 91.3% of the patients whose serum AFP had increased before cryoablation returned to normal or nearly normal levels during postoperative 3 6 months. Complications of cryoablation included liver capsular cracking in one patient, transient thrombocytopenia in 4 patients and asymptomatic right sided pleural effusions in 2 patients. Two patients developed liver abscess at the previous cryoablation sites after postoperative 2 and 4 months respectively and recovered after the treatment with antibiotics and drainage. Conclusions Percutaneous cryoablation may offer a safe and effective option for patients with HCC that cannot be surgically removed.

OBJECTIVES: This research was performed to explore the effect of macrophage migration inhibitory factor (MIF) on the apoptosis of bone marrow mesenchymal stem cells (BMSCs) in ischemia and hypoxia environments. METHODS: The cell viability of BMSCs incubated under hypoxia/ischemia (H/I) conditions with or without pretreatment with MIF or triglycidyl isocyanurate (TGIC) was detected using cell counting kit-8 (CCK-8) analysis. Plasmids containing long noncoding RNA (lncRNA) maternally expressed gene 3 (MEG3) or β-catenin small interfering RNA (siRNA) were used to overexpress or downregulate the corresponding gene, and the p53 signaling pathway was activated by pretreatment with TGIC. The influences of MIF, overexpression of lncRNA MEG3, activation of the p53 signaling pathway, and silencing of β-catenin on H/I-induced apoptosis of BMSCs were revealed by western blotting, flow cytometry, and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining. RESULTS: From the results of CCK-8 assay, western blotting, and flow cytometry, pretreatment with MIF significantly decreased the H/I-induced apoptosis of BMSCs. This effect was inhibited when lncRNA MEG3 was overexpressed by plasmids containing MEG3. The p53 signaling pathway was activated by TGIC, and β-catenin was silenced by siRNA. From western blot results, the expression levels of β-catenin in the nucleus and phosphorylated p53 (p-p53) were downregulated and upregulated, respectively, when the lncRNA MEG3 was overexpressed. Through flow cytometry, MIF was also shown to significantly alleviate the increased reactive oxygen species (ROS) level of BMSCs caused by H/I. CONCLUSIONS In summary, we conclude that MIF protected BMSCs from H/I-induced apoptosis by downregulating the lncRNA MEG3/p53 signaling pathway, activating the Wnt/β-catenin signaling pathway, and decreasing ROS levels.
Humans ; RNA, Long Noncoding/metabolism* ; Macrophage Migration-Inhibitory Factors/metabolism* ; beta Catenin/metabolism* ; Reactive Oxygen Species/metabolism* ; Sincalide/metabolism* ; Tumor Suppressor Protein p53/metabolism* ; Apoptosis ; Mesenchymal Stem Cells ; Wnt Signaling Pathway/genetics* ; RNA, Small Interfering/metabolism* ; Hypoxia/metabolism* ; Ischemia ; Bone Marrow Cells